Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

CDC Scientist Kept Quiet About Flu Blunder

August 18, 2014 2:02 pm | by Mike Stobbe, AP Medical Writer | News | Comments

A government scientist kept silent about a potentially dangerous lab blunder and revealed it only after workers in another lab noticed something fishy, according to an internal investigation. Read more...              

TOPICS:

Allergan Names New CFO Amid Valeant Struggle

August 18, 2014 1:31 pm | News | Comments

Botox maker Allergan, which is fighting a hostile takeover bid from Valeant Pharmaceuticals, has named longtime executive Jim Hindman its new chief financial officer. Read more...                    

TOPICS:

UK Agrees to Re-Review Prostate Cancer Drug

August 18, 2014 11:16 am | News | Comments

Ferring Pharmaceuticals confirmed that, following an oral hearing in London, the panel upheld Ferring's appeal against the National Institute for Health and Care Excellence's final appraisal determination for the use of Firmagon as an option for treating advanced hormone-dependent prostate cancer. Read more...

TOPICS:
Advertisement

Daiichi Sankyo Kicks Off Etanercept Biosimilar Trial

August 18, 2014 11:11 am | News | Comments

Daiichi Sankyo Co. Ltd., in collaboration with the U.S. company Coherus BioSciences Inc., announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (the RApsody trial) in Japan. Read more...

TOPICS:

Pfizer Submits NDA for Breast Cancer Drug

August 18, 2014 11:04 am | News | Comments

Pfizer Inc. announced it has completed the submission of a New Drug Application to the U.S. Food and Drug Administration for palbociclib in combination with letrozole for the treatment of postmenopausal women with ER+/HER2- breast cancer who have not received previous systemic treatment for advanced disease. Read more...

TOPICS:

Eisai Seeks Marketing Approvals for Anticancer Drug in Europe, U.S.

August 18, 2014 10:56 am | News | Comments

Eisai Co. Ltd. announced that it has submitted applications to regulatory authorities in the U.S. and Europe for marketing approval of its novel in-house developed anticancer agent lenvatinib mesylate as a treatment for progressive radioiodine-refractory differentiated thyroid cancer. Read more...

TOPICS:

Microchip Tracks Cancer Cell Migration

August 18, 2014 10:50 am | News | Comments

Using a microengineered device that acts as an obstacle course for cells that leaves just enough space for the cells to weave their way through, researchers have shed new light on a cellular metamorphosis thought to play a role in tumor cell invasion throughout the body. Read more...

TOPICS:

Ebola Quarantine Escapees Return

August 18, 2014 10:39 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Some of the people who fled an Ebola quarantine center in a Liberian slum when it was looted over the weekend are again under observation at a hospital Monday, as authorities struggle to contain the spread of an Ebola outbreak in West Africa. Read more...

TOPICS:
Advertisement

Coherus' Humira Biosimilar Hits Primary Endpoint

August 15, 2014 2:28 pm | News | Comments

Coherus BioSciences Inc. announced that CHS-1420, its proposed biosimilar of adalimumab (Humira), met the primary endpoint in a pivotal clinical pharmacokinetic similarity study that compared CHS-1420 to Humira in healthy subjects. Read more...   

TOPICS:

FDA Committee Backs BI's COPD Drug

August 15, 2014 2:22 pm | News | Comments

Boehringer Ingelheim announced that the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted that existing data supports approval of investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with COPD. Read more...

TOPICS:

Isis Earns $2M from the Advancement of SMA Drug

August 15, 2014 2:07 pm | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy. Read more...    

TOPICS:

Watch Yourself: Device Data May Improve Parkinson's Research, Monitoring

August 15, 2014 2:01 pm | Videos | Comments

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Intel Corporation announced a collaboration aimed at improving research and treatment for Parkinson’s disease. Read more...                  

TOPICS:

New Focus on Drugs Made in Tobacco Plants

August 15, 2014 1:47 pm | by Malcolm Ritter, AP Science Writer | News | Comments

It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. Using plants this way- sometimes called "pharming"- can produce complex and valuable proteins for medicines. Read more...

TOPICS:

10 Things You Might Not Know About Ebola

August 15, 2014 1:09 pm | by Christina Jakubowski, News Editor | News | Comments

The 2014 outbreak of Ebola virus in West Africa has the world on high alert. Currently deemed an international public health emergency by the WHO, the virus has racked up more than 1,060 deaths and sickened 1,975 – making it the deadliest Ebola outbreak ever.

TOPICS:

Mallinckrodt Acquires Questcor Pharmaceuticals

August 15, 2014 10:27 am | News | Comments

Mallinckrodt plc, a leading global specialty pharmaceutical company, announced that it has completed its acquisition of Questcor Pharmaceuticals Inc. in a cash and stock transaction valued at approximately $5.8 billion following strong approval by both Mallinckrodt and Questcor shareholders. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading